Santini, Daniele http://orcid.org/0000-0002-9118-3337
Banna, Giuseppe Luigi http://orcid.org/0000-0003-0764-3650
Buti, Sebastiano http://orcid.org/0000-0003-0876-0226
Isella, Luca http://orcid.org/0009-0001-3002-9715
Stellato, Marco http://orcid.org/0000-0002-0993-7540
Roberto, Michela http://orcid.org/0000-0001-5339-8348
Iacovelli, Roberto http://orcid.org/0000-0002-1750-2117
Funding for this research was provided by:
Astellas Pharma
Università degli Studi di Parma
Article History
Accepted: 4 September 2023
First Online: 19 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Daniele Santini has received fees for Advisory Board from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Janssen, Merck, MSD, Novartis, Pfizer, and Roche. Giuseppe Luigi Banna has received fees for speaker bureau from AstraZeneca and Astellas and travel accommodation expenses coverage for medical conferences from Janssen. Sebastiano Buti has received honoraria for speaking at scientific events and advisory roles from AstraZeneca, Bristol Myers Squibb, Ipsen, MSD, Novartis, and Pfizer and research funding from Novartis. Michela Roberto has received speaker fees from Ipsen, Novartis, MSD, and Bristol Myers Squibb and travel accommodation expenses coverage for medical conferences from Janssen and Astellas. Roberto Iacovelli has received advisory board fees from AAA, Astellas, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, and Sanofi and acted as a consultant for Astellas, Eisai, MSD, and Pfizer. Luca Isella and Marco Stellato have no conflicts of interest to disclose.